Lactobacillus gasseri
- Generic Name
- Lactobacillus gasseri
- Drug Type
- Biotech
- Unique Ingredient Identifier
- Q66E0D2443
- Associated Conditions
- Vaginal Flora Imbalance
Synbiotic Supplementation to Prevent Preterm Birth: A Multi-Center Trial
• A multi-center, randomized, placebo-controlled trial is underway to investigate the efficacy of synbiotic supplementation in preventing spontaneous preterm birth (sPTB).
• Pregnant women at risk for sPTB between 80/7 and 106/7 weeks of gestation will receive either a synbiotic containing eight Lactobacillus strains or a placebo daily until delivery.
• The primary outcome is gestational age at delivery, with secondary outcomes including PTB rates, PPROM rates, vaginal microbiome analysis, and neonatal outcomes.
• The trial aims to recruit 402 participants across seven Belgian teaching hospitals over approximately 36 months to determine if synbiotics can prolong pregnancy and improve neonatal health.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath